AccurKardia is an ECG-led diagnostics software company transforming ECG signals into a broad biomarker and diagnostic tool for disease management in cardiology and beyond. Our mission is to improve patient outcomes and save lives on a global scale. Our flagship product, AccurECG™, is an FDA-cleared (Class II SaMD), cloud-based, device-agnostic software providing fully automated ECG interpretation, capable of detecting up to 13 arrhythmias. It assists cardiac monitoring companies in analyzing ECGs from holters, event recorders, and cardiac telemetry devices, significantly enhancing efficiency and patient care. Recently, AccurKardia reached a major milestone with the FDA Breakthrough Device Designation for our AI-driven ECG-based Aortic Valve Stenosis (AK-AVS) screening software. This achievement highlights our dedication to advancing early detection and precision medicine in cardiovascular care. We are also proud participants in the MedTech Innovator 2024 Cohort and the Heart & Brain Health Accelerator track, in collaboration with the American Heart Association’s Center for Health Technology and Innovation.
External link for AccurKardia
101 Avenue of the Americas
New York, NY 10013, US
AccurKardia reposted this
2024 has been an amazing year for AccurKardia—and we’re just getting started! Check out our video for a peek at this year’s highlights, and stay tuned for what’s on the horizon in 2025. Wishing you all a happy, healthy, and prosperous New Year! #2024Highlights #NewYear #Innovation #ECG #BetterOutcomes
2024 has been an amazing year for AccurKardia—and we’re just getting started! Check out our video for a peek at this year’s highlights, and stay tuned for what’s on the horizon in 2025. Wishing you all a happy, healthy, and prosperous New Year! #2024Highlights #NewYear #Innovation #ECG #BetterOutcomes
From everyone at AccurKardia we wish you a cheerful and festive Christmas! May your days be filled with joy, warmth, and good health this holiday season. Here’s to celebrating together and looking forward to what’s to come! #MerryChristmas #HolidayWishes #BetterOutcomes #ECG #EKG #Innovation
Healthcare Disparities in Aortic Stenosis Diagnosis and Treatment A recent study in JACC: Advances examines how residential racial segregation affects aortic stenosis (AS) diagnosis and transcatheter aortic valve implantation (TAVI) rates among Medicare patients. The results reveal significant disparities in care access, particularly for Black patients in highly segregated areas. Learn more: https://lnkd.in/e6gFN4Qs We are addressing this inequity with AK-AVS, our AI-powered, non-invasive diagnostic tool for AS. By leveraging widely available ECG data, AK-AVS enables scalable, early detection and helps ensure equitable access to care across all zip codes in America.
In a recent Medsider interview with Scott Nelson our CEO, Juan C Jimenez, shared how AccurKardia is transforming medtech innovation through a lean, strategic approach and relentless execution. Scott captured this concept perfectly: 💡 “If 80% of your capital goes to commercialization instead of development, ROI is exponentially stronger.” With our FDA-cleared AccurECG™ and Breakthrough Device Designation for AK-AVS™, we’re proving that impactful results come from smart execution. Check out the full interview to discover how we’re driving innovation and better patient outcomes.
“If you're staring down $50 million in capital to get to a point where you're actually selling product, if 80% of that capital was used in the development versus maybe the opposite, where 80% is now being used to commercialize it, there's going to be a much stronger ROI in the latter scenario.” Meet Juan C Jimenez, a former investment banker and previous President of Puerto Rico’s largest non-emergency medical transportation company, TransCita, now bringing his fresh perspectives to #medtech. Juan co-founded AccurKardia with a mission to streamline ECG interpretation and make cardiac diagnostics more accessible and efficient with AI. AccurKardia’s platform is designed to fully automate ECG interpretation, reducing time and costs for cardiac monitoring companies. Their flagship product, AccurECG, has earned FDA 510(k) clearance, too. Here's a sneak peek at Juan’s conversation with Scott Nelson: 💸 Capital efficiency can often be more valuable than flashy, oversized funding rounds. Focus on scaling sustainably without unnecessary dilution by keeping your organization lean and focused. 🛠️ Focus on developing your product and thoroughly understanding your market before inviting investors to join your venture. Allow your team space to develop a solid foundation before bringing in external opinions to ensure that early investor feedback doesn’t misalign or dilute your core vision. 🤝 Prioritize genuine relationships, transparency, and rigorous standards to build credibility and lasting partnerships. Be upfront about both your strengths and limitations and embrace a proactive approach to validation. Click the link in the comments for the full interview. This Medsider episode was brought to you by FastWave Medical, a hot IVL startup in the cardiovascular space. Don’t miss out on their next fundraise (more details in the comments). P.S. - We recently launched Medsider Mentors Volume VI, which is packed with insights and learnings from founders and CEOs of some of the most dynamic medical device and health technology startups in the world. Click the link in the comment section for this latest edition now available exclusively to our premium members.
A recent publication by the American Heart Association Presidential Advisory Group projects that annual U.S. healthcare costs for cardiovascular diseases could escalate from $400 billion in 2020 to $1.344 trillion by 2050. At AccurKardia, we're dedicated to improving patient outcomes and saving lives, which in turn helps mitigate this economic burden. Our advanced, device-agnostic ECG analytics enable early detection and proactive management of cardiac conditions, aiming to reduce costs through predictive capabilities. https://lnkd.in/gcJriiSP
AccurKardia reposted this
Join us at the HITLAB Innovators Summit 2024 as our Chief Product Officer, Moin Hussaini, takes the stage to share insights on a groundbreaking topic: “Screening Health System ECGs for Undiagnosed Aortic Stenosis to Enable Earlier Intervention and Improved Outcomes.” 🗓️ Date: Tuesday, December 3, 2024 📍 Location: Microsoft Tech Center, NYC ⏰ Session Time: 2:30 PM Discover how AccurKardia is leveraging advanced AI-driven ECG interpretation to revolutionize cardiac care. Our mission is to enhance early detection, improve patient outcomes, and save lives through innovative solutions like AccurECG and AK-AVS. 💡 Don’t miss this opportunity to learn about the future of diagnostics and how we’re addressing one of cardiology’s greatest challenges: Aortic Stenosis. We can’t wait to connect with you in person. Let’s shape the future of healthcare together! #HITLABSummit #DigitalHealth #HealthTech #BetterOutcomes #Innovation
AI is transforming healthcare, and as this Washington Post editorial highlights, it’s a revolution that’s ultimately good for humanity. From improving diagnostic accuracy to expanding access to care, AI is helping address some of the biggest challenges in medicine. We invite you to explore this thought-provoking piece and join the conversation about how AI is reshaping healthcare for the better. https://lnkd.in/e8HVdB4u
This Thanksgiving, we at AccurKardia want to take a moment to express our heartfelt gratitude. We are deeply thankful for the incredible dedication and hard work of the entire AccurKardia team, whose commitment drives our mission to transform ECG data into a more powerful diagnostic and broad biomarker. We are equally grateful to our collaborators, advisors, research partners, and commercial partners for their invaluable support and trust in our journey. Your contributions have been vital in advancing innovation and improving patient care. Wishing everyone a Happy Thanksgiving filled with joy, gratitude, and togetherness. Here’s to continuing our shared journey to make a lasting impact in human lives. #HappyThanksgiving #Gratitude #AccurKardia #Innovation #Healthcare
Join us at the HITLAB Innovators Summit 2024 as our Chief Product Officer, Moin Hussaini, takes the stage to share insights on a groundbreaking topic: “Screening Health System ECGs for Undiagnosed Aortic Stenosis to Enable Earlier Intervention and Improved Outcomes.” 🗓️ Date: Tuesday, December 3, 2024 📍 Location: Microsoft Tech Center, NYC ⏰ Session Time: 2:30 PM Discover how AccurKardia is leveraging advanced AI-driven ECG interpretation to revolutionize cardiac care. Our mission is to enhance early detection, improve patient outcomes, and save lives through innovative solutions like AccurECG and AK-AVS. 💡 Don’t miss this opportunity to learn about the future of diagnostics and how we’re addressing one of cardiology’s greatest challenges: Aortic Stenosis. We can’t wait to connect with you in person. Let’s shape the future of healthcare together! #HITLABSummit #DigitalHealth #HealthTech #BetterOutcomes #Innovation